EAM
SRPT icon

EverPoint Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

EverPoint Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-945,600
Closed -$58.1M – 516
2016
Q3 		$58.1M Buy
945,600
+395,600
+72% +$12M 1.05% 12
2016
Q2 		$10.5M Buy
+550,000
New +$10.2M 0.21% 135

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EverPoint Asset Management's SRPT Position: Q4 2016 in Review

EverPoint Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 38% in Q4 2016, selling an estimated $9.18M and leaving 371,554 shares worth $10.2M. The position accounts for 0.19% of the portfolio, ranked #140.

EverPoint Asset Management first reported a position in SRPT in Q3 2016 and has held it in 2 quarters since. The position peaked at $36.8M in Q3 2016. 177 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • EverPoint Asset Management held 371,554 shares of Sarepta Therapeutics worth $10.2M as of Q4 2016.
  • EverPoint Asset Management sold 228,446 Sarepta Therapeutics shares in Q4 2016, an estimated $9.18M.
  • Sarepta Therapeutics made up 0.19% of EverPoint Asset Management's portfolio in Q4 2016, its #140 holding.
  • EverPoint Asset Management first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 2 quarters since.
  • EverPoint Asset Management's Sarepta Therapeutics position peaked at $36.8M in Q3 2016.
  • 177 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.